Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Vet Comp Oncol. 2018 Aug 13;16(4):606–615. doi: 10.1111/vco.12428

FIGURE 2.

FIGURE 2

Pevonedistat decreases cell viability of primary canine large B-cell lymphoma samples. A, CellTilter96 AQueous one solution cell proliferation assays show that pevonedistat decreases the viability of four primary canine lymphoma samples. B, MTS assay of three canine normal lymph node samples. The percentage of growth was normalized to the DMSO-treated control group. ****P < 0.0001. Data was presented as mean ± SD